Drugs / Endocalyx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05205005 | May 2022 → Mar 2024 | type 2 diabetes mellitus | VA Office of Research and Development | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Endocalyx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205005 ↗ |
| Modality | Other / unclassified | “a dietary supplement that contains glycocalyx precursors (glucosamine sulfate, fucoidan, superoxide dismutase, and high molecular weight hyaluronan)” NCT05205005 ↗ |